Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

July 30, 2026

Conditions

Hemodialysis

Interventions

DRUG

Sacubitril-valsartan

sacubitril/valsartan

DRUG

Placebo

Trial Locations (1)

RECRUITING

Brigham and Women's, Boston

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Brigham and Women's Hospital

OTHER